Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 650

2.

Factors influencing the quality of life perception in patients with type 2 diabetes mellitus.

Timar R, Velea I, Timar B, Lungeanu D, Oancea C, Roman D, Mazilu O.

Patient Prefer Adherence. 2016 Dec 8;10:2471-2477. doi: 10.2147/PPA.S124858.

3.

Gastric bypass surgery reveals independency of obesity and diabetes melitus type 2.

Fenger M, Hansen DL, Worm D, Hvolris L, Kristiansen VB, Carlsson ER, Madsbad S.

BMC Endocr Disord. 2016 Nov 9;16(1):59.

4.

Body mass index and the risk of cancer incidence in patients with type 2 diabetes in Japan: Results from the National Center Diabetes Database.

Yamamoto-Honda R, Takahashi Y, Yoshida Y, Kwazu S, Iwamoto Y, Kajio H, Yanai H, Mishima S, Shimbo T, Noda M.

J Diabetes Investig. 2016 Nov;7(6):908-914. doi: 10.1111/jdi.12522.

5.

Prediction of the 20-year incidence of diabetes in older Chinese: Application of the competing risk method in a longitudinal study.

Liu X, Fine JP, Chen Z, Liu L, Li X, Wang A, Guo J, Tao L, Mahara G, Tang Z, Guo X.

Medicine (Baltimore). 2016 Oct;95(40):e5057.

6.

Physiological and behavioral risk factors of type 2 diabetes mellitus in rural India.

Barik A, Mazumdar S, Chowdhury A, Rai RK.

BMJ Open Diabetes Res Care. 2016 Aug 2;4(1):e000255. doi: 10.1136/bmjdrc-2016-000255.

7.

Dietary carbohydrate intake, presence of obesity and the incident risk of type 2 diabetes in Japanese men.

Sakurai M, Nakamura K, Miura K, Takamura T, Yoshita K, Nagasawa SY, Morikawa Y, Ishizaki M, Kido T, Naruse Y, Nakashima M, Nogawa K, Suwazono Y, Sasaki S, Nakagawa H.

J Diabetes Investig. 2016 May;7(3):343-51. doi: 10.1111/jdi.12433.

8.

Impact of cardiovascular risk factors on carotid intima-media thickness: sex differences.

Łoboz-Rudnicka M, Jaroch J, Bociąga Z, Rzyczkowska B, Uchmanowicz I, Polański J, Dudek K, Szuba A, Łoboz-Grudzień K.

Clin Interv Aging. 2016 May 23;11:721-31. doi: 10.2147/CIA.S103521.

9.

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.

Kashiwagi A, Yoshida S, Nakamura I, Kazuta K, Ueyama E, Takahashi H, Satomi H, Kosakai Y, Kawamuki K.

J Diabetes Investig. 2016 Jul;7(4):544-54. doi: 10.1111/jdi.12471.

10.

Characteristics of Registered Diabetics in Dhank Province in the Sultanate of Oman.

Al-Rubaee FR, Al-Abri MH.

Oman Med J. 2016 May;31(3):205-10. doi: 10.5001/omj.2016.39.

11.

Major Increase in Microbiota-Dependent Proatherogenic Metabolite TMAO One Year After Bariatric Surgery.

Trøseid M, Hov JR, Nestvold TK, Thoresen H, Berge RK, Svardal A, Lappegård KT.

Metab Syndr Relat Disord. 2016 May;14(4):197-201. doi: 10.1089/met.2015.0120.

12.

Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus.

Rondanelli M, Perna S, Astrone P, Grugnetti A, Solerte SB, Guido D.

Patient Prefer Adherence. 2016 Mar 24;10:407-13. doi: 10.2147/PPA.S97383.

13.

Effect of Vagal Nerve Blockade on Moderate Obesity with an Obesity-Related Comorbid Condition: the ReCharge Study.

Morton JM, Shah SN, Wolfe BM, Apovian CM, Miller CJ, Tweden KS, Billington CJ, Shikora SA.

Obes Surg. 2016 May;26(5):983-9. doi: 10.1007/s11695-016-2143-y.

14.

Clinical and Patient-Related Variables Associated with Initiating GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Patients in Primary Care in Germany.

Qiao Q, Grandy S, Hiller J, Kostev K.

PLoS One. 2016 Mar 28;11(3):e0152281. doi: 10.1371/journal.pone.0152281.

15.

Risk Factors for Hypogonadism in Male Patients with Type 2 Diabetes.

Zheng R, Cao L, Cao W, Chu X, Hu Y, Zhang H, Xu J, Sun H, Bao W, Liu K, Liu C.

J Diabetes Res. 2016;2016:5162167. doi: 10.1155/2016/5162167.

16.

Sitagliptin/Metformin Versus Insulin Glargine Combined With Metformin in Obese Subjects With Newly Diagnosed Type 2 Diabetes.

Ji M, Xia L, Cao J, Zou D.

Medicine (Baltimore). 2016 Mar;95(11):e2961. doi: 10.1097/MD.0000000000002961.

17.

SNPs in FNDC5 (irisin) are associated with obesity and modulation of glucose and lipid metabolism in Saudi subjects.

Al-Daghri NM, Mohammed AK, Al-Attas OS, Amer OE, Clerici M, Alenad A, Alokail MS.

Lipids Health Dis. 2016 Mar 11;15:54. doi: 10.1186/s12944-016-0224-5.

18.

Mechanisms Regulating Insulin Response to Intragastric Glucose in Lean and Non-Diabetic Obese Subjects: A Randomized, Double-Blind, Parallel-Group Trial.

Meyer-Gerspach AC, Cajacob L, Riva D, Herzog R, Drewe J, Beglinger C, Wölnerhanssen BK.

PLoS One. 2016 Mar 4;11(3):e0150803. doi: 10.1371/journal.pone.0150803.

19.

Long-term mortality and incidence of cardiovascular diseases and type 2 diabetes in diabetic and nondiabetic obese patients undergoing gastric banding: a controlled study.

Pontiroli AE, Zakaria AS, Mantegazza E, Morabito A, Saibene A, Mozzi E, Micheletto G; LAGB10 working group..

Cardiovasc Diabetol. 2016 Feb 27;15:39. doi: 10.1186/s12933-016-0347-z.

20.

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus.

Neeland IJ, McGuire DK, Chilton R, Crowe S, Lund SS, Woerle HJ, Broedl UC, Johansen OE.

Diab Vasc Dis Res. 2016 Mar;13(2):119-26. doi: 10.1177/1479164115616901.

Items per page

Supplemental Content

Loading ...
Support Center